Os Tibiale Externum: The Hidden Bone of the Foot

The human foot is a marvel of anatomical engineering, comprising 26 bones, 33 joints, and more than 100 muscles, tendons, and ligaments working in concert to support the full weight of the body. Yet, for all this complexity, the foot occasionally harbours an additional, uninvited structure: the os tibiale externum, more commonly known as the accessory navicular. Though small and often overlooked, this sesamoid-like bone carries considerable clinical significance and has fascinated anatomists, podiatrists, and orthopaedic surgeons for centuries.

What Is the Os Tibiale Externum?

The os tibiale externum is an accessory ossicle — a supernumerary bone — located on the medial (inner) side of the foot, adjacent to the navicular bone. The navicular itself sits along the inner arch of the foot, articulating with the talus proximally and the three cuneiform bones distally. The os tibiale externum develops as a secondary centre of ossification within the substance of, or immediately adjacent to, the posterior tibial tendon’s insertion site on the navicular. It is encased within this tendon or connected to the navicular by a fibrous or fibrocartilaginous bridge, a junction known as a synchondrosis.

This accessory bone is one of the most common accessory ossicles found in the human foot, with an estimated prevalence of between 4% and 21% of the general population, depending on the imaging modality and study population used. It presents bilaterally — in both feet — in approximately 50 to 90% of affected individuals, suggesting a strong genetic underpinning. It is slightly more common in females than males, and it tends to become symptomatic during adolescence when the foot is undergoing rapid growth and the demands placed on the musculoskeletal system intensify.

Classification and Anatomy

Anatomists and clinicians have long recognised that the os tibiale externum does not present in a uniform fashion. The most widely accepted classification system divides it into three distinct types.

Type I is the smallest variant, a true sesamoid bone fully embedded within the posterior tibial tendon, typically measuring 2 to 3 millimetres. It sits entirely within the tendon substance and is usually an incidental finding on imaging, rarely causing symptoms.

Type II is the most clinically relevant variant and the one most commonly associated with pain. It is a larger ossicle, typically between 8 and 12 millimetres, connected to the navicular by a synchondrosis — a fibrocartilaginous union. This junction is biomechanically vulnerable. Under repetitive loading and torsional stress, the synchondrosis can become inflamed, develop microfractures, or fail entirely, producing the clinical syndrome known as accessory navicular syndrome or os tibiale externum syndrome.

Type III, sometimes called the cornuate navicular, represents a fully fused accessory ossicle that has united with the navicular proper. This produces a characteristically enlarged, horn-shaped navicular visible on plain radiographs. Because fusion has occurred, Type III is generally asymptomatic, though the altered morphology of the navicular may influence the mechanics of the arch.

Clinical Presentation and Symptoms

The os tibiale externum is often asymptomatic throughout an individual’s lifetime, discovered only incidentally on imaging performed for an unrelated reason. However, when symptoms do arise, they typically manifest as medial midfoot pain, tenderness directly over the navicular prominence, and swelling in the region of the inner arch. The overlying skin may become irritated, particularly in individuals who wear tight or poorly fitting footwear.

Symptoms most commonly emerge during adolescence, often coinciding with periods of rapid skeletal growth, increased physical activity, or both. Flat foot deformity — pes planus — is frequently associated with symptomatic accessory navicular, as a lowered medial longitudinal arch places the posterior tibial tendon under greater mechanical strain, transmitting increased stress across the synchondrosis. Activities that involve repeated inversion and eversion of the foot, such as running, dancing, and team sports, are common triggers.

Acute exacerbation can also result from direct trauma to the medial foot. A forced eversion injury — such as a rolled ankle — may stress or rupture the synchondrosis acutely, mimicking or co-existing with a navicular fracture and presenting a diagnostic challenge in the emergency setting. High-resolution imaging, including MRI, is invaluable in these scenarios, revealing bone marrow oedema, synchondral disruption, and tendon pathology that plain radiographs cannot adequately depict.

Diagnosis

Diagnosis begins with a thorough clinical assessment. A clinician will observe the contour of the medial arch, assess for the characteristic medial navicular prominence, and identify point tenderness with direct palpation. Functional assessment includes evaluating heel-rise capacity, assessing for pes planus, and examining the integrity and strength of the posterior tibial tendon.

Plain radiographs, particularly the medial oblique view, reliably demonstrate the ossicle and allow classification by type. MRI provides superior soft tissue resolution and is the gold standard for assessing the degree of synchondral inflammation, bone marrow changes, and posterior tibial tendon integrity. Technetium bone scintigraphy has historically been used to demonstrate increased uptake at the synchondrosis, confirming active stress response, though MRI has largely supplanted it in contemporary practice.

Treatment

Management is stratified according to symptom severity. Conservative treatment is the first-line approach and succeeds in the majority of cases. Rest, activity modification, and the use of non-steroidal anti-inflammatory medications can reduce acute inflammation. Orthotics designed to support the medial arch and offload the navicular prominence are particularly effective, redistributing stress away from the synchondrosis. Immobilisation in a short-leg cast or a removable walking boot is reserved for more severe or refractory presentations, allowing the inflamed synchondrosis to settle over a period of weeks.

When conservative measures fail after three to six months, surgical intervention becomes appropriate. The Kidner procedure — excision of the accessory ossicle with advancement and reattachment of the posterior tibial tendon to the navicular — remains the most commonly performed operation. Modern variations aim to preserve tendon function and restore medial arch support. Outcomes are generally favourable, with the large majority of patients reporting significant pain relief and a return to full activity.

The os tibiale externum is a small but clinically meaningful anatomical variant that sits at the intersection of embryology, biomechanics, and musculoskeletal medicine. Its presence is common, its expression variable, and its capacity to generate significant pain in active individuals well documented. Understanding its classification, the mechanisms by which it becomes symptomatic, and the spectrum of treatment options available allows clinicians to manage affected patients effectively — restoring comfort, function, and quality of life from a bone that, by rights, was never meant to be there at all.

The Treatment of Onychomycosis in the Foot

Onychomycosis — fungal infection of the nail — is one of the most prevalent dermatological conditions encountered in podiatric practice, accounting for approximately 50% of all nail disorders. It is caused primarily by dermatophytes, most commonly Trichophyton rubrum and Trichophyton mentagrophytes, though non-dermatophyte moulds and Candida species are increasingly recognised as causative organisms, particularly in immunocompromised individuals. The condition disproportionately affects the toenails over the fingernails, and its prevalence rises markedly with age, peripheral vascular disease, diabetes mellitus, and immunosuppression. Despite being perceived by some as a cosmetic nuisance, onychomycosis carries significant clinical implications including pain, difficulty ambulating, secondary bacterial infection, and considerable psychological distress. Effective management therefore demands a thorough, evidence-based approach.

Diagnosis Before Treatment

Accurate diagnosis is the essential prerequisite to any treatment programme. Clinical presentation alone — thickened, discoloured, dystrophic nails — is insufficient to confirm onychomycosis, as similar appearances can result from psoriasis, trauma, lichen planus, and other non-fungal conditions. Mycological confirmation via nail clippings sent for microscopy and culture remains the gold standard, with a sensitivity improved further by polymerase chain reaction (PCR) testing where available. Commencing antifungal therapy without laboratory confirmation risks not only treatment failure but unnecessary systemic drug exposure and cost.

Topical Antifungal Therapy

For mild to moderate onychomycosis — particularly distal and lateral subungual onychomycosis with less than 50% nail plate involvement and no matrix involvement — topical antifungal agents represent a reasonable first-line option. Amorolfine 5% nail lacquer, applied weekly, and ciclopirox 8% nail lacquer, applied daily, are the most widely used preparations. These agents penetrate the nail plate and exert their fungicidal activity directly at the site of infection, avoiding systemic side effects.

However, topical monotherapy has significant limitations. Penetration through the nail plate is inherently difficult, and cure rates with topical agents alone are modest — typically ranging from 5–15% mycological cure at 48 weeks for amorolfine monotherapy in distal subungual onychomycosis. Newer topical agents, including efinaconazole 10% solution and tavaborole 5% solution, demonstrate superior penetration profiles and have shown improved mycological cure rates in clinical trials, reaching 53% and 31% respectively in pivotal studies. These agents represent an advance in topical therapy, particularly for patients in whom systemic treatment is contraindicated.

Topical treatment is most effective when combined with nail debridement — the mechanical reduction of nail thickness — which reduces the fungal burden and improves drug penetration. Podiatrists routinely perform debridement as an adjunct to both topical and systemic treatment.

Systemic Antifungal Therapy

For moderate to severe onychomycosis, matrix involvement, or failure of topical therapy, systemic antifungal agents are the treatment of choice and offer substantially higher cure rates. Two oral agents dominate current practice: terbinafine and the triazole antifungals, principally itraconazole.

Terbinafine, an allylamine that inhibits squalene epoxidase and thus ergosterol synthesis, is considered the gold standard for dermatophyte onychomycosis. A continuous 12-week course for toenail infection achieves mycological cure rates of approximately 70–80%, with complete cure rates (mycological plus clinical) of around 35–50%. Its fungicidal rather than fungistatic mode of action and its high nail keratin affinity contribute to its efficacy. Terbinafine is generally well tolerated, though clinicians must remain alert to rare but serious adverse effects including hepatotoxicity and severe cutaneous reactions such as Stevens-Johnson syndrome. Baseline liver function testing is recommended in those with pre-existing liver disease.

Itraconazole, a triazole that inhibits cytochrome P450-dependent lanosterol 14?-demethylase, may be administered continuously (200 mg daily for 12 weeks) or via pulse dosing (400 mg daily for one week per month, for three pulses). Pulse therapy reduces drug accumulation and cost while retaining acceptable efficacy, with mycological cure rates of approximately 54–63% for toenail infection. Itraconazole has a broader spectrum of activity than terbinafine, making it preferable for non-dermatophyte and Candida-associated infections. Its significant cytochrome P450 3A4 inhibition creates numerous drug interactions, and its negative inotropic properties necessitate caution in patients with cardiac failure.

Fluconazole, administered weekly at 150–300 mg, represents an alternative for patients intolerant of or contraindicated to first-line agents, though evidence for its use in toenail onychomycosis is less robust.

Laser and Device-Based Therapies

Over the past decade, laser therapy has attracted considerable attention as a non-pharmacological treatment option. Nd:YAG lasers operating at 1064 nm, as well as diode and fractional CO2 lasers, have been investigated. The proposed mechanism involves selective photothermal destruction of fungal organisms within the nail. While short-term mycological improvement has been reported, systematic reviews have found the evidence for laser therapy to be of generally low quality, with heterogeneous methodologies and high recurrence rates. Laser treatment is not currently recommended as a primary therapy by major dermatological or podiatric guidelines, though it may have a role as an adjunct or in patients unable to tolerate pharmacological treatment.

Photodynamic therapy (PDT), using photosensitising agents activated by visible light, has also been explored with some promise, particularly for milder cases, but similarly awaits more robust evidence before entering mainstream practice.

Surgical and Mechanical Interventions

Surgical nail avulsion — partial or complete removal of the nail plate — is occasionally employed, particularly when there is marked thickening preventing adequate drug penetration, or in the context of painful subungual hyperkeratosis. Chemical avulsion using 40% urea preparations offers a less invasive alternative, softening and dissolving the nail plate over several weeks to facilitate drug delivery and reduce fungal burden.

Permanent nail ablation via matricectomy — chemical (phenol), surgical, or laser — may be considered in refractory cases or where quality of life is severely impacted by recurrent infection, accepting the consequence of permanent nail loss.

Recurrence and Prevention

Recurrence following successful treatment is a major challenge, affecting up to 50% of patients within five years. Contributing factors include re-infection from environmental reservoirs (shoes, socks, communal areas), concurrent tinea pedis, and host susceptibility factors. Long-term management must therefore incorporate prophylactic measures: antifungal foot powders, replacement of contaminated footwear, treatment of concurrent tinea pedis, and patient education on hygiene practices in communal bathing environments. In high-risk individuals — particularly those with diabetes or peripheral vascular disease — regular podiatric monitoring and preventive nail care are essential components of ongoing management.

The treatment of onychomycosis in the foot requires a patient-centred, stepwise approach guided by accurate diagnosis, severity assessment, and individual risk factors. While topical agents suffice for mild disease, systemic antifungals — principally terbinafine — remain the cornerstone of treatment for most cases. Mechanical debridement, adjunctive topical therapy, and preventive education are integral to achieving durable cure. Emerging technologies such as novel topical agents and laser therapy broaden the therapeutic landscape, though further evidence is needed to establish their definitive role. Given its high prevalence, tendency to recur, and impact on quality of life, onychomycosis warrants the careful, sustained clinical attention that effective podiatric practice affords.

Onitsuka Tiger: The Sole of a Legacy

There is a particular kind of cool that cannot be manufactured — it must be earned. Onitsuka Tiger has earned it over seven decades, threading its way from the rubble of postwar Japan to the feet of fashion editors, film icons, and athletes alike. It is a brand that has outlasted trends, survived corporate reinvention, and emerged not merely intact but celebrated. To wear Onitsuka Tiger is to participate in a lineage — part sporting history, part cultural mythology, entirely its own thing.

Origins in the Ashes

The story begins in Kobe, Japan, in 1949. Kihachiro Onitsuka was a young entrepreneur, thirty years old and possessed of a particular conviction: that sport could rebuild a nation’s spirit. Japan had just emerged from the devastation of World War II, and Onitsuka believed that physical activity — specifically, giving young people proper footwear for it — could restore a sense of purpose and dignity to a demoralised generation. He founded Onitsuka Co., Ltd. with modest capital and an almost missionary sense of purpose.

His first product was a basketball shoe, and it was here that one of footwear’s most charming origin stories was born. Struggling to design a sole that would grip the court effectively, Onitsuka reportedly found inspiration while eating octopus — the suction cups on the tentacles suggesting a pattern that could grip almost any surface. The resulting sole became a hallmark of early Onitsuka craftsmanship: functional, ingeniously observed, and rooted in everyday Japanese life.

The Tiger Stripes

By the mid-1950s, Onitsuka had shifted focus to running shoes, and in 1953 introduced the design element that would define the brand forever: the distinctive side stripe, or “tiger stripes,” that run diagonally from the sole up the lateral side of the upper. Originally a structural feature intended to reinforce the shoe, these stripes became the brand’s visual identity. Simple, bold, and immediately recognisable, they gave Onitsuka Tiger an aesthetic language that has never needed updating — only reinterpreting.

The 1960s were a period of intense global ambition. Onitsuka’s shoes were selected for Japanese athletes competing in the 1964 Tokyo Olympics, an extraordinary moment of national pride and international exposure. The shoes performed. Athletes noticed. The brand’s reputation spread beyond Japan’s borders, reaching American and European markets at a moment when running culture was beginning its long ascent into mainstream consciousness.

The American Connection

The American chapter of Onitsuka Tiger’s story involves a young accounting student named Phil Knight, who would later co-found Nike. In 1962, Knight visited the Onitsuka factory in Kobe and negotiated the rights to distribute Tiger shoes in the United States under the name Blue Ribbon Sports. For nearly a decade, Onitsuka Tigers were the performance running shoe of choice among serious American athletes — before the relationship fractured and Knight went on to build his own empire.

This episode, dramatised in Knight’s memoir Shoe Dog and later in the television series Full Count, is a reminder of how central Onitsuka Tiger was to the birth of global sneaker culture. The brand was not peripheral to that story — it was the inciting incident. It taught an American entrepreneur what a great athletic shoe could be, and the lessons learned on those Kobe factory floors rippled outward to shape the entire industry.

Kill Bill and the Cultural Moment

No account of Onitsuka Tiger’s cultural life would be complete without Quentin Tarantino. In 2003, Kill Bill: Volume 1 placed a pair of yellow and black Onitsuka Tiger Mexico 66s on Uma Thurman’s feet as she carved her way through the Crazy 88. The shoe — sleek, retro, undeniably cool — became the film’s most imitated fashion detail almost overnight. Orders surged. A generation of cinephiles who had never heard of Onitsuka Tiger went looking for those yellow shoes.

It was a masterclass in accidental branding, or perhaps deliberate brilliance — Tarantino is, after all, a connoisseur of authentic cool. The Mexico 66, originally launched in 1966 and named for the Mexico City Olympics, is now the brand’s most iconic silhouette: low-profile, clean-lined, with just enough vintage character to feel both nostalgic and current. It has been reissued in hundreds of colourways and remains one of the most recognisable shoes in the sneaker world.

The Asics Years and Renewed Independence

In 1977, Onitsuka merged with two other companies to form Asics — a name derived from the Latin phrase Anima Sana In Corpore Sano, meaning “a healthy soul in a healthy body.” For years, the Onitsuka Tiger brand was largely dormant, subsumed into Asics’ performance athletic identity. It was relaunched as a lifestyle and fashion label in 2002, operating under the Asics umbrella but with its own distinct creative direction — retro-influenced, fashion-forward, and firmly pointed at a different consumer than the serious runner reaching for Asics Gel-Kayanos.

This distinction matters. Onitsuka Tiger occupies a unique position: it carries the credibility of genuine athletic heritage without pretending to be a performance brand. It is honest about its identity — a fashion label grounded in history — and that honesty is part of its appeal. In an era when many brands manufacture heritage they don’t actually possess, Onitsuka Tiger’s decades of real history function as a kind of luxury.

Design Philosophy and Contemporary Appeal

Today, Onitsuka Tiger’s design language balances reverence and reinvention. The core archive — Mexico 66, California 78, Serrano, Fabre — is treated with curatorial seriousness, with seasonal colourways and collaborations that refresh without undermining. Collaborations with designers including Andrea Pompilio and Walter Van Beirendonck have positioned the brand firmly within high fashion, while the mainline collection maintains accessibility.

The shoes themselves remain distinctively Japanese in their construction philosophy: meticulous, considered, and attentive to materials. There is a quietness to Onitsuka Tiger design — a preference for understatement that reads as confidence rather than timidity. Where many sneaker brands scream for attention, Onitsuka Tiger tends to murmur, and somehow people lean in to listen.

A Legacy Still Being Written

What makes Onitsuka Tiger enduring is not nostalgia alone, though nostalgia plays its part. It is the coherence of a brand that has always known what it believed in: the dignity of craft, the beauty of functional design, the idea that a shoe can carry meaning beyond its materials. Kihachiro Onitsuka wanted to rebuild a nation’s spirit through sport. He built something longer-lasting than he likely imagined — a pair of stripes that still, seventy-five years on, mean something to the people who wear them.

That is a rare kind of legacy. And it fits perfectly.

Heavy Burdens: How Obesity Affects the Feet

The human foot is an engineering marvel — a complex structure of 26 bones, 33 joints, and more than 100 muscles, tendons, and ligaments, all working in precise coordination to bear the weight of the body with every step. But that marvel has limits. When excess body weight is placed upon it year after year, the foot begins to fail in ways that are painful, progressive, and often underappreciated. Obesity — defined as a body mass index (BMI) of 30 or above — places enormous mechanical and systemic stress on the feet, contributing to a wide range of conditions that can profoundly diminish quality of life.

The Mechanical Burden

The most immediate way obesity harms the feet is through sheer mechanical load. During normal walking, each foot absorbs a force equivalent to roughly 1.25 times a person’s body weight with every step. During running or stair climbing, that force can multiply to three or four times body weight. For someone who is obese, this means the structures of the foot are subjected to vastly greater pressure than they were designed to handle, day after day, year after year.

This sustained overloading has consequences at every level. The arches of the foot — the medial longitudinal arch in particular — are placed under exceptional strain. The plantar fascia, the thick band of connective tissue that supports the arch and runs from the heel to the base of the toes, becomes chronically stretched and inflamed. The result is plantar fasciitis, one of the most common and debilitating foot conditions in the world, and one that is significantly more prevalent among people with obesity. Sufferers typically experience a stabbing pain in the heel, worst during the first steps of the morning, that can persist for months or years if left untreated.

Related to plantar fasciitis is the progressive flattening of the foot that accompanies obesity. As the arch collapses under excess weight, the foot pronates — rolling inward — changing the biomechanics of the entire lower limb. This altered gait does not stay confined to the foot. It places additional stress on the ankles, knees, hips, and lower back, creating a cascade of musculoskeletal problems that often accompany obesity-related foot dysfunction.

Joint Disease and Arthritis

Obesity is one of the strongest modifiable risk factors for osteoarthritis, and the joints of the foot are not exempt. The subtalar joint, the midfoot joints, and the metatarsophalangeal joints — particularly that of the big toe — all bear excess load in obese individuals. Over time, the cartilage that cushions these joints wears away, leading to pain, stiffness, swelling, and reduced range of motion.

Gout, a form of inflammatory arthritis caused by the accumulation of uric acid crystals in joints, is also strongly associated with obesity. The big toe joint is the classic site of a gout attack, which presents as sudden, excruciating pain, redness, and swelling so severe that even the weight of a bed sheet can be intolerable. Obesity promotes hyperuricemia — elevated uric acid in the blood — by reducing the kidneys’ ability to excrete uric acid and by increasing its production through metabolic pathways linked to excess fat tissue.

Vascular and Neuropathic Complications

Obesity is a primary driver of type 2 diabetes, and the feet are among the organs most devastated by diabetic complications. Peripheral arterial disease — the narrowing of blood vessels in the legs and feet — reduces circulation to the extremities. At the same time, peripheral neuropathy damages the nerves of the feet, causing pain, tingling, numbness, or a complete loss of sensation.

The combination of poor circulation and reduced sensation is particularly dangerous. Minor injuries — a blister, a small cut, a pressure sore — may go unnoticed and untreated because the patient cannot feel them. Without adequate blood supply to support healing and immune defence, these wounds can develop into chronic ulcers that resist treatment. In severe cases, infection spreads to underlying bone and tissue, and amputation becomes necessary. Lower limb amputations are among the most feared and devastating complications of diabetic foot disease, and obesity is a central driver of the diabetes that precedes them.

Skin and Soft Tissue Problems

The feet of people with obesity are also vulnerable to a range of skin and soft tissue problems. Increased sweating and skin-to-skin contact in skin folds can create warm, moist environments in which fungal infections — particularly tinea pedis, or athlete’s foot — thrive. These infections cause itching, scaling, and cracking of the skin, and if left untreated, can open pathways for bacterial invasion.

Calluses and corns develop in response to the abnormal pressure patterns created by excessive body weight and altered gait. While these are the body’s attempt to protect vulnerable skin, they can themselves become painful and, in diabetic patients, can progress to ulceration. Swelling of the feet and ankles — peripheral oedema — is also common in obesity, resulting from both the mechanical obstruction of lymphatic and venous return by excess tissue and from the cardiac and renal strain that frequently accompanies chronic obesity.

Psychological and Social Dimensions

The impact of obesity-related foot problems extends beyond the purely physical. Chronic foot pain limits mobility, making exercise more difficult — which in turn makes weight management harder, creating a vicious cycle that can feel impossible to escape. Reduced physical activity contributes to social isolation, depression, and a declining sense of self-efficacy. Shoe fitting becomes a practical challenge as foot shape changes, and the indignity of limited footwear options adds to the psychological burden.

For many people, foot pain is not merely an inconvenience but a barrier to participation in ordinary life: shopping, walking with family, standing at work. When the feet fail, independence erodes.

A Path Forward

Understanding the profound impact of obesity on foot health underscores the importance of early intervention and preventive care. Weight reduction — even modest losses of five to ten percent of body weight — measurably reduces the mechanical load on the feet and can significantly alleviate plantar fasciitis, joint pain, and swelling. Appropriate footwear, custom orthotics, physiotherapy, and regular podiatric care can help manage existing conditions and prevent deterioration.

Ultimately, the feet are both victims and messengers. The pain they generate is a signal that the body is under systemic strain — strain that, if addressed, can be reduced. The connection between obesity and foot health is a compelling reminder that the consequences of excess weight are not abstract or distant, but immediate, concrete, and felt with every step.

Nocturnal Leg Cramps: Understanding the Night-Time Intruder

Few experiences are as jarring as being woken from a deep sleep by a sudden, vice-like pain seizing the muscles of the leg. This is the hallmark of nocturnal leg cramps (NLCs) — involuntary, painful muscle contractions that occur at night, most commonly in the calf, though the thighs and feet are not immune. Known colloquially as “charley horses,” these episodes are far more than a minor inconvenience. For millions of people worldwide, they represent a chronic disruption to sleep, wellbeing, and quality of life. Understanding their prevalence, causes, mechanisms, and management is essential — not only for those who experience them, but for the health professionals who support them.

Prevalence and Who Is Affected

Nocturnal leg cramps are remarkably common. Research indicates that between 50 and 60 percent of adults report experiencing them at some point, with approximately 30 percent of adults experiencing them at least five times per month. They affect both sexes, though they are slightly more prevalent among women, and their frequency increases considerably with age. Children are not entirely spared — around 7 percent of children also report nocturnal cramps — but the condition is predominantly one of adulthood and older age. Concerningly, up to 20 percent of sufferers experience symptoms bothersome enough to seek medical attention, speaking to the very real impact these episodes can have on daily functioning and mental health.

What Happens During a Cramp?

A nocturnal leg cramp is an involuntary contraction of a muscle that occurs without the individual’s intention or control. The episode typically begins suddenly and without warning. The muscle — most often the gastrocnemius (the large calf muscle) or the soleus beneath it — tightens into a hard, palpable knot. The pain can be severe, lasting on average around nine minutes per episode, though in some cases it may persist longer. Even after the spasm passes, residual soreness and tenderness can linger for hours, sometimes for the remainder of the following day. When cramps recur across multiple nights, or cluster in episodes throughout a single night, the cumulative sleep disruption can contribute to secondary insomnia, daytime fatigue, anxiety about sleep, and reduced overall wellbeing.

Causes and Contributing Factors

The precise mechanism behind nocturnal leg cramps remains incompletely understood, but research points most strongly to muscle fatigue and nerve dysfunction as the primary drivers, rather than the electrolyte imbalances that are commonly assumed to be responsible. That said, the picture is rarely simple, and a range of factors — lifestyle, medical, and pharmacological — can heighten an individual’s susceptibility.

Lifestyle and postural factors play a significant role. Prolonged sitting, particularly in positions that shorten the calf muscles, reduces blood supply to the legs and increases cramping risk. Standing for long periods on hard surfaces such as concrete has a similar effect. Sleeping in the supine position with feet pointed downward (plantar flexion) shortens the calf muscles during rest, making nocturnal spasms more likely. Conversely, overexertion — too much high-intensity physical activity — can fatigue the muscles sufficiently to trigger cramping during the subsequent night’s rest.

Medical conditions associated with nocturnal leg cramps include peripheral vascular disease, lumbar spinal stenosis, liver cirrhosis, chronic kidney failure, diabetic peripheral neuropathy, hyperthyroidism, and electrolyte disturbances such as low calcium or elevated potassium. Pregnancy is also a well-recognised trigger, particularly in the later trimesters. Notably, while these associations are clinically important to identify, the evidence does not always show that treating the underlying condition reliably resolves the cramps — suggesting the relationship is complex and multifactorial.

Medications are another important contributor. Several pharmacological agents are strongly associated with nocturnal leg cramps, including intravenous iron sucrose, conjugated oestrogens, raloxifene, naproxen, teriparatide, diuretics, statins, and corticosteroids. Clinicians should review a patient’s medication history when cramps are a presenting complaint, as substituting or adjusting the implicated drug may bring meaningful relief.

Differential Diagnosis

Not all nocturnal leg pain is caused by true muscle cramps. Several conditions can mimic or be confused with Nocturnal leg cramps, and accurate diagnosis is essential. Restless legs syndrome (RLS) is perhaps the most commonly confused alternative — it involves an urge to move the legs rather than a painful contraction and is typically relieved by movement rather than muscle stretching. Peripheral arterial claudication causes leg pain on exertion and is related to ischaemia. Myositis (muscle inflammation) and peripheral neuropathy can also produce leg discomfort at night. A thorough history and physical examination are usually sufficient to differentiate these conditions; laboratory investigations and specialised testing are rarely required to confirm Nocturnal leg cramps.

Management and Treatment

Managing nocturnal leg cramps encompasses both immediate relief and longer-term prevention. When a cramp strikes, the most effective immediate intervention is to stretch the affected muscle. For a calf cramp, this involves flexing the foot upward (dorsiflexion) — standing up and pressing the heel flat to the floor, or pulling the toes upward while seated. Massaging the area and applying warmth can also help relax the muscle and alleviate pain more quickly.

For prevention, a programme of regular calf and lower limb stretching — especially before bed — has good evidence behind it. Reviewing sleeping posture to avoid sustained plantar flexion is also beneficial; some individuals find that sleeping with a pillow to prop the feet in a neutral position reduces frequency. Staying well hydrated and avoiding excessive exercise in the hours before bed may further reduce risk.

In cases where cramps are frequent and disruptive, pharmacological options have been explored. Historically, quinine was widely prescribed and found to be effective, but its use is now restricted in many countries due to serious cardiac side effects. Magnesium supplementation, vitamin B complex, gabapentin, and muscle relaxants such as carisoprodol or orphenadrine have all been trialled with varying degrees of success. No single pharmacological agent has emerged as universally preferred, and treatment should always be individualised with reference to the patient’s overall health profile and comorbidities.

The Role of the Podiatrist

Podiatrists are particularly well-positioned to assess and manage nocturnal leg cramps given their expertise in lower limb biomechanics, footwear, and neuromuscular function. Gait analysis can reveal postural contributors to muscle fatigue; orthotic intervention may reduce strain on the calf and foot musculature; and foot positioning advice can minimise cramping during sleep. Podiatrists also serve an important role in identifying when Nocturnal leg cramps may be symptomatic of vascular or neurological conditions warranting referral to other specialists.

Nocturnal leg cramps are a common, often underestimated clinical problem with real consequences for sleep, mood, and daily life. While frequently benign and idiopathic, they may in some cases reflect underlying medical conditions or medication effects that warrant investigation. A thoughtful approach — combining patient education, lifestyle modification, postural strategies, stretching, and where appropriate, pharmacological support — offers the best chance of meaningful, sustained relief. No one should simply accept that disruptive nights of pain are inevitable.

Night Splints in the Treatment of Plantar Fasciitis 

Plantar fasciitis is the most common cause of heel pain in adults, affecting an estimated one in ten people at some point during their lifetime. Characterised by degeneration and inflammation of the plantar fascia at its proximal insertion on the medial calcaneal tubercle, the condition produces a well-recognised clinical pattern: sharp, stabbing heel pain that is most intense with the first steps of the morning or after periods of prolonged rest. This "post-static dyskinesia" is the hallmark of the condition and provides the conceptual basis for one of its most widely used conservative treatments — the night splint.

Night splints have been a mainstay of plantar fasciitis management for several decades. By maintaining the foot and ankle in a position of dorsiflexion throughout sleep, they aim to counteract the pathological processes that underlie morning pain. Understanding why night splints work requires an appreciation of the biomechanical and histological mechanisms driving the condition, and their clinical application is best understood within the broader context of evidence-based conservative care.

## Pathophysiology and the Rationale for Night Splints

The plantar fascia functions as a passive tension band along the undersurface of the foot, supporting the medial longitudinal arch and facilitating efficient propulsion during gait. Repetitive mechanical loading — particularly in individuals with limited ankle dorsiflexion, excessive body weight, prolonged weight-bearing occupations, or biomechanical abnormalities such as pes planus or pes cavus — leads to cumulative microtrauma at the fascial origin. This produces a cycle of failed healing and degenerative change rather than true acute inflammation, a process more accurately termed plantar fasciopathy in contemporary literature.

During sleep, the foot naturally rests in a position of plantarflexion. In this position, the plantar fascia and the intrinsic musculature of the foot are in a shortened, relaxed state. When the individual rises and bears weight, the sudden tensile loading of these contracted structures produces the characteristic pain of the first steps. Over time, nocturnal shortening may contribute to ongoing fascial tightness and impair the tissue's capacity for repair.

The night splint directly addresses this mechanism. By holding the ankle in a neutral or mildly dorsiflexed position — typically five to fifteen degrees — throughout the sleeping hours, the device maintains a gentle, sustained stretch on both the plantar fascia and the Achilles tendon-gastrocnemius-soleus complex. This prolonged low-load stretching promotes fascial elongation, reduces morning contracture, and — according to some researchers — may facilitate the remodelling of collagen fibres within the healing tissue. The result, for many patients, is a meaningful reduction in first-step pain and an improvement in overall function.

## Types of Night Splints

Night splints are available in two principal designs: posterior splints and anterior (or dorsal) splints.

Posterior night splints are the traditional design, consisting of a rigid or semi-rigid shell that runs along the back of the lower leg and under the foot, secured with straps. They hold the ankle in dorsiflexion and are effective at maintaining the desired position throughout the night. However, their bulk and rigidity are frequently cited by patients as uncomfortable, leading to poor compliance — a critical limitation in any treatment that requires nightly use over an extended period.

Anterior or dorsal night splints address this concern by positioning the shell along the front of the lower leg and the dorsum of the foot, leaving the heel and posterior calf free. Patients generally report these to be more comfortable and less disruptive to sleep, and compliance rates tend to be higher. A third variant, the sock-style or "strassburg sock," applies a gentle dorsiflexion force through a strap connected from the toe of a compression sock to the knee. While less rigid than splinted designs, it is particularly well tolerated and has demonstrated efficacy in clinical trials.

The choice between designs should be guided by individual patient factors, including tolerance, sleep position, and the degree of ankle dorsiflexion restriction. Fitting and patient education are essential: the splint must be worn consistently — ideally every night — for a minimum of one to three months to achieve meaningful benefit.

## Clinical Evidence

The evidence supporting night splints for plantar fasciitis is generally positive, though the quality of available research is variable. Multiple randomised controlled trials and systematic reviews have demonstrated that night splints produce significant reductions in pain and improvements in function compared to baseline, and are broadly comparable to other conservative interventions such as stretching programmes, orthotics, and corticosteroid injections in terms of short-to-medium-term outcomes.

A landmark study by Batt, Tanji, and Skattum demonstrated that patients using night splints alongside a standard stretching programme achieved superior outcomes compared to stretching alone. Similarly, a well-cited trial by Powell and colleagues found that night splints were significantly more effective than anti-inflammatory medication and activity modification in reducing first-step pain at eight weeks. The Strassburg sock has been evaluated in a prospective controlled trial, with results showing resolution of symptoms in the majority of participants within a mean of approximately eight weeks.

Notably, night splints appear to be particularly effective for patients with chronic plantar fasciitis — defined as symptoms persisting for more than six months — who have failed to respond to other conservative measures. In this subgroup, the addition of a night splint to an existing treatment programme frequently produces the breakthrough improvement that other modalities alone had not achieved.

## Integration into a Treatment Plan

Night splints are rarely employed in isolation. Best practice dictates their use as part of a multimodal conservative approach that may include calf and plantar fascia stretching, load management, foot orthoses, footwear modification, and — where indicated — shockwave therapy or physiotherapy-guided exercise rehabilitation. Patient education regarding the chronic, self-limiting nature of the condition, combined with realistic expectations about the timeline for recovery, is fundamental to engagement and adherence.

Compliance remains the single greatest barrier to success with night splint therapy. Clinicians should discuss this openly with patients, acknowledge the challenges of wearing a device during sleep, and explore which design is most likely to suit the individual's lifestyle and sleeping habits.


Night splints represent a well-established, biomechanically rational, and evidence-supported intervention in the conservative management of plantar fasciitis. By maintaining a sustained dorsiflexion stretch throughout the night, they directly target the nocturnal fascial shortening that underlies the condition's most disabling symptom — first-step morning pain. When appropriately selected, correctly fitted, and used consistently as part of a comprehensive treatment programme, night splints can produce meaningful clinical improvement and accelerate recovery, particularly in patients with chronic or refractory symptoms. They remain a valuable and accessible tool in the podiatric and sports medicine clinician's armamentarium.

New Balance Running Shoes: A Legacy Built One Step at a Time

In the crowded world of athletic footwear, few brands have managed to build a reputation as enduring and respected as New Balance. While names like Nike and Adidas dominate pop culture and billion-dollar marketing campaigns, New Balance has carved out a distinctive identity rooted in something more fundamental: the quality of the run itself. From the dedicated marathoner logging pre-dawn miles to the casual jogger finding their stride on a weekend morning, New Balance running shoes have become synonymous with comfort, performance, and a quiet kind of authenticity that resonates deeply with those who take their running seriously.

A Brand Born from the Ground Up

New Balance was founded in Boston, Massachusetts, in 1906 — not as a shoe company, but as an arch support manufacturer. William Riley created flexible arch supports inspired by a chicken’s foot, believing that the natural balance a bird achieves through its three-pronged stance could be replicated in footwear for humans. It was a humble beginning, but it planted the seed of a philosophy that would define the brand for over a century: that the foundation of great movement starts from the ground up.

It wasn’t until the 1960s that New Balance pivoted decisively toward running shoes, producing some of the first performance-oriented trainers aimed at serious runners. By 1976, their Trackster model was named the best running shoe on the market by a leading sports magazine — a landmark moment that announced New Balance as a genuine force in athletic footwear. The brand had arrived, and it had done so on the merits of its product rather than the power of celebrity endorsements.

The Philosophy of Fit

One of the most distinguishing features of New Balance’s approach to running shoes is its commitment to fit diversity. While many competitors offer shoes in standard widths, New Balance has long provided options ranging from narrow (2A) to extra-wide (4E and beyond). This seemingly simple decision reflects a profound understanding of the runner: that feet come in all shapes and sizes, and a shoe that doesn’t fit correctly is not just uncomfortable — it can be the source of injury, inefficiency, and discouragement.

For runners with wide feet, flat arches, or other anatomical considerations that fall outside the “average,” finding a well-fitting running shoe can feel like a nearly impossible task. New Balance has consistently addressed this gap, making the brand a trusted ally for runners who have long been overlooked by mainstream athletic footwear. This inclusive approach has cultivated fierce brand loyalty, particularly among older runners, long-distance athletes, and those returning to running after injury.

Flagship Models and Technological Innovation

New Balance’s running lineup spans a wide spectrum, from lightweight racing shoes to heavily cushioned daily trainers, and the brand has invested significantly in developing proprietary technologies to underpin each category.

The Fresh Foam platform, introduced in 2014, represents one of the brand’s most successful innovations. Using data-driven design and advanced computational modelling, Fresh Foam midsoles are engineered to deliver a plush, cushioned ride that adapts naturally to the runner’s gait. The Fresh Foam X 1080 — widely considered the pinnacle of the Fresh Foam line — is a shoe that has earned a devoted following among long-distance runners and those who demand maximum comfort on high-mileage training days. Its generous stack height and smooth, rolling ride make it a trusted companion for marathon training and recovery runs alike.

On the performance end of the spectrum, the FuelCell series brings a different energy to the table. FuelCell foam is engineered for propulsion, offering a firmer, more responsive feel that suits faster-paced training and racing. The FuelCell Rebel and FuelCell SuperComp Trainer have become go-to options for runners who want speed without sacrificing the reliability that New Balance is known for. The SuperComp Trainer, featuring a carbon fibre plate embedded within the midsole, places New Balance firmly in the elite category of super-shoes that have transformed competitive distance running in recent years.

The 860 and 880 series serve as the backbone of New Balance’s stability and neutral trainer offerings respectively. These workhorse shoes have evolved through numerous iterations while retaining the core qualities that made them popular — reliable structure, durable outsoles, and a consistent, trustworthy ride that day-after-day runners can depend on.

Made in the USA: A Commitment Worth Noting

In an era when nearly all athletic footwear is manufactured in Asia, New Balance stands apart as one of the only major brands to still produce shoes domestically. Their New England factories — located in Massachusetts and Maine — continue to manufacture a range of shoes on American soil, employing skilled workers and maintaining quality control practices that the brand considers a point of genuine pride.

This is not simply a marketing talking point. New Balance’s domestic manufacturing represents a tangible commitment to a different kind of value system — one that prioritises craftsmanship, local employment, and long-term quality over short-term cost reduction. For many consumers, knowing that their shoes were made by American workers in American factories adds a layer of meaning to their purchase that no amount of celebrity sponsorship can replicate.

The Cultural Moment

In recent years, New Balance has experienced something of a cultural renaissance. Once affectionately (and sometimes mockingly) associated with middle-aged dads and sensible footwear choices, the brand has undergone a remarkable reappraisal in style circles. Collaborations with high-fashion designers, limited-edition colourways, and organic adoption by streetwear communities have repositioned New Balance as a genuinely cool brand — one that has earned its cultural cachet without abandoning its roots.

Crucially, this cultural elevation has not come at the expense of performance. The same shoes that appear on fashion runways and in lifestyle editorials are the same shoes trusted by elite athletes and everyday runners. New Balance has managed the rare feat of becoming both fashionable and functional — a balance (fittingly) that many brands struggle to achieve.

New Balance running shoes endure because they are built on a foundation of genuine purpose. From their early days as arch support specialists to their current status as one of the most respected names in performance running, the brand has remained anchored to the belief that a great shoe exists to serve the runner — not the other way around. With a commitment to fit diversity, technological innovation, domestic manufacturing, and authentic performance, New Balance has earned its place not just on the feet of millions of runners, but in the broader story of what it means to move well. In a world of noise and spectacle, New Balance keeps things simple: lace up, step out, and run.

The Neuropad Test: Assessing Diabetic Peripheral Neuropathy at the Point of Care

Diabetic peripheral neuropathy (DPN) is one of the most prevalent and debilitating complications of diabetes mellitus, affecting up to 50% of people living with the condition over their lifetime. It is a major driver of foot ulceration, lower limb amputation, and cardiovascular autonomic dysfunction, carrying significant burdens for both patients and healthcare systems. Early, accurate detection is therefore critical — yet standard neurological assessments can be time-consuming, require specialist equipment, and are poorly suited to routine clinical settings. Into this gap has stepped the Neuropad, a simple, point-of-care indicator test that detects sudomotor (sweat gland) dysfunction as a proxy marker for small autonomic nerve fibre damage. Understanding how it works, what the evidence says, and where it fits in clinical practice is essential for clinicians managing diabetes.

How Neuropad Works

Neuropad is a small adhesive plaster developed by TRIGOcare International and designed for application to the plantar (sole) surface of the foot. The pad contains anhydrous cobalt (II) chloride — a blue compound that undergoes a well-characterised colour change when it absorbs water. When applied to the skin for ten minutes, a normal sudomotor response causes the pad to turn from blue to pink, reflecting adequate moisture from sweat glands. An abnormal or incomplete colour change — the pad remaining blue or turning only partially pink — indicates reduced or absent sweating, which is a hallmark of small autonomic C-fibre dysfunction.

The test is patented as a ten-minute screening tool for early detection of diabetic foot syndrome. It is non-invasive, painless, and requires no specialised equipment beyond the plaster itself, making it readily deployable in primary care, diabetes clinics, or even as a patient self-test at home. At a list price of approximately £7.28 per test (as assessed by NICE), it is substantially more affordable than nerve conduction studies or skin biopsy.

The Scientific Basis: Sudomotor Dysfunction in Neuropathy

Sweating in the feet is regulated by postganglionic cholinergic sympathetic nerve fibres — small, unmyelinated C-fibres that are among the earliest structures damaged in diabetic neuropathy. Sudomotor dysfunction therefore represents an early and sensitive marker of neuropathic change, often preceding clinical symptoms and detectable deficits in large-fibre tests such as vibration perception or nerve conduction velocity.

This biological rationale lends Neuropad particular relevance to the detection of small-fibre neuropathy — a form of DPN that traditional assessments poorly capture. Established tools such as the Neuropathy Disability Score (NDS) and nerve conduction studies (NCS) predominantly assess large myelinated fibres, and can miss early small-fibre involvement entirely.

Diagnostic Performance

The evidence base for Neuropad has grown substantially over the past two decades, with numerous clinical studies examining its sensitivity, specificity, and correlation with established neuropathy markers.

A landmark 2008 study by Quattrini et al., published in Diabetologia, evaluated 57 diabetic patients using Neuropad alongside quantitative sensory testing, autonomic function assessments, and intra-epidermal nerve fibre density from skin biopsy. The results demonstrated meaningful correlations between Neuropad responses and the NDS, neuropathic symptom scores, cold detection thresholds, and deep-breathing heart rate variability — reflecting both somatic and autonomic neuropathic involvement.

Subsequent studies have further characterised its performance profile. Across assessments against large-fibre neuropathy markers — such as the NDS and peroneal motor nerve conduction velocity — Neuropad demonstrates high sensitivity (typically 80–95%) but moderate specificity (50–70%). This pattern makes it well-suited as a screening tool: a normal result reliably reduces the likelihood of clinically significant neuropathy, but an abnormal result warrants further investigation.

Importantly, diagnostic accuracy is meaningfully improved when Neuropad is assessed against small-fibre measures. A 2014 study by Ponirakis and colleagues found that, compared with corneal nerve fibre length — a sensitive marker of small-fibre damage assessed by corneal confocal microscopy — Neuropad achieved a sensitivity of 83% and specificity of 80%, with an area under the ROC curve (AUC) of 85%. This outperformed its performance against both the NDS (AUC 66%) and peroneal motor nerve conduction velocity (AUC 70%), underscoring the test’s specific utility for small C-fibre assessment.

An important refinement involves moving beyond simple binary (pink/blue) interpretation to quantifying the rate of colour change. A study examining automated image analysis (Sudometrics) demonstrated that continuous colour-change output substantially improved diagnostic accuracy, achieving high sensitivity and specificity for autonomic dysfunction (91% and 83% respectively) and small-fibre neuropathy (88% and 78%), compared with the weaker specificity of the categorical reading alone.

Research has also established Neuropad’s reproducibility. A study in 142 type 2 diabetic patients found a highly significant correlation (r = 0.91) between repeat measurements of time to complete colour change, indicating strong test-retest reliability.

Autonomic Neuropathy and Cardiovascular Risk

Beyond peripheral neuropathy, Neuropad has been evaluated as a tool for detecting cardiovascular autonomic neuropathy (CAN) — a potentially life-threatening condition associated with silent myocardial ischaemia, arrhythmia, and increased mortality. Time to complete colour change correlates significantly with the Valsalva ratio, a standard autonomic function test, as well as with symptoms of DPN and postural hypotension. A cut-off of fifteen minutes for complete colour change has been identified as an optimal threshold, improving specificity for both CAN and DPN without compromising sensitivity.

Given that CAN often goes undetected until advanced stages, the ability of a simple plaster to prompt further autonomic evaluation is clinically meaningful.

Limitations and Clinical Considerations

Neuropad is not without limitations. Its moderate specificity, particularly against large-fibre assessments, means a positive result should not be used in isolation for diagnosis. Environmental factors — ambient temperature, skin moisture, and humidity — may influence the rate and completeness of colour change, adding variability to qualitative readings. Age, BMI, renal function, and alcohol use have also been identified as potential confounders of sudomotor function independent of glycaemic status.

In elderly populations with diabetes or pre-diabetes, the KORA F4 survey found reasonable sensitivity but low specificity for polyneuropathy diagnosis, with a positive predictive value as low as 33.6%. This supports positioning Neuropad as a triage or exclusion test rather than a standalone diagnostic.

NICE evaluated Neuropad under its Medical Technologies Guidance programme (MTG38, 2018), recommending it as an option for detecting early DPN, particularly in settings where more specialised testing is unavailable. The guidance acknowledged its ease of use and potential value in identifying patients who require further assessment.

Conclusion

The Neuropad test occupies a valuable niche in the clinical assessment of diabetic neuropathy. By providing a simple, inexpensive, and non-invasive window into sudomotor and small C-fibre function, it enables early detection of neuropathic changes that traditional large-fibre assessments routinely miss. Its high sensitivity makes it particularly effective as a screening and exclusion tool, and its performance improves markedly when interpreted quantitatively or benchmarked against small-fibre measures. While it should not replace comprehensive neurological evaluation, Neuropad represents a practical and evidence-based addition to the diabetic foot assessment toolkit — one that can meaningfully support earlier intervention and reduce the risk of serious complications.

Treatment of a Navicular Stress Fracture

The navicular is a small, boat-shaped bone nestled at the top of the midfoot, bridging the hindfoot and forefoot and playing a central role in the transmission of weight-bearing forces during gait. Despite its modest size, the navicular is particularly vulnerable to stress injury, and a navicular stress fracture is widely regarded as one of the most challenging and consequential injuries in sports medicine. Left undertreated or mismanaged, it can result in delayed union, avascular necrosis, or complete fracture displacement — outcomes that may permanently derail an athlete’s career. Understanding the principles behind its treatment is therefore essential for clinicians, athletes, and allied health practitioners alike.

Why the Navicular Is Vulnerable

The navicular’s susceptibility to stress fracture stems from its precarious blood supply and biomechanical loading environment. The central third of the bone receives relatively poor vascularisation, creating a watershed zone that is slow to heal once injured. During high-impact activities — sprinting, jumping, cutting — repetitive compressive and shear forces concentrate in this region, gradually fatiguing the bone’s microarchitecture before any macroscopic crack becomes visible on plain X-ray. This is why navicular stress fractures are notorious for being missed in the early stages, often misdiagnosed as midfoot sprains or non-specific dorsal foot pain. Delayed diagnosis is itself a major risk factor for poor outcomes, underscoring the need for prompt imaging when a stress fracture is suspected.

Diagnosis and Imaging

Plain radiographs are notoriously insensitive for navicular stress fractures, detecting fewer than half of confirmed cases. When clinical suspicion exists — typically in a track athlete or footballer presenting with dorsal midfoot pain, tenderness on direct palpation of the “N-spot,” and pain provoked by single-leg hopping — advanced imaging is mandatory. CT scanning is the gold standard for characterising fracture type, extent, and displacement, and is used to guide treatment decisions. MRI is highly sensitive for detecting bone marrow oedema in early cases and is particularly useful when the CT appears normal but symptoms persist. Fractures are commonly classified using the Torg system into three grades: incomplete cortical break (Type I), complete fracture without displacement (Type II), and complete fracture with displacement or comminution (Type III).

Non-Operative Management

For Type I and uncomplicated Type II fractures, non-operative management remains a well-supported first-line approach, provided strict adherence to the protocol is observed. The cornerstone of conservative treatment is non-weight-bearing immobilisation in a below-knee cast for a minimum of six weeks. The emphasis on non-weight-bearing is critical — partial weight-bearing has been associated with significantly higher rates of delayed union and re-fracture. During this period, the athlete typically uses crutches and is prohibited from any impact loading of the affected limb.

Following the immobilisation phase, healing is confirmed with repeat CT imaging rather than relying on symptom resolution alone, as clinical improvement often precedes radiological union. Once healing is confirmed, a graded return to weight-bearing is initiated, typically over a further four to six weeks. Running and sport-specific activities are reintroduced progressively under clinical supervision, with a full return to competition generally expected between four and six months from the onset of treatment. Functional rehabilitation during this phase focuses on restoring proprioception, calf strength, and dynamic foot stability — all factors that reduce recurrence risk.

Operative Management

Surgical intervention is indicated for Type III fractures, fractures that have failed conservative management (defined as persistent non-union or re-fracture), and increasingly in elite athletes where a faster, more reliable return to sport is prioritised. The standard surgical technique involves internal fixation using one or two cannulated compression screws inserted along the long axis of the navicular, compressing the fracture site and providing mechanical stability. In cases with established non-union, bone grafting — either autograft from the iliac crest or synthetic alternatives — may be incorporated to stimulate biological healing at the sclerotic fracture margins.

Post-operative management mirrors the conservative protocol in many respects: non-weight-bearing immobilisation for six weeks, followed by progressive rehabilitation once CT-confirmed union is achieved. However, surgical fixation provides the mechanical advantage of compressing the fracture site throughout healing, potentially reducing the risk of re-displacement and offering a more predictable timeline. Studies comparing operative and non-operative outcomes in elite athletes have generally favoured surgery for time to return to sport, with surgical cohorts demonstrating higher rates of complete union and lower recurrence compared to conservative management — though the body of evidence remains relatively modest given the fracture’s overall rarity.

Rehabilitation and Return to Sport

Regardless of whether management is operative or conservative, rehabilitation is a phased, progressive process that must not be rushed. After confirmed radiological union, athletes begin pool running and cycling to maintain cardiovascular fitness before any land-based impact loading is introduced. Straight-line jogging precedes change-of-direction work, and sport-specific drills are added only once the athlete can tolerate sustained running without pain. Throughout this process, load monitoring and athlete education are paramount — navicular stress fractures carry a meaningful recurrence risk, particularly in athletes who return to full training prematurely or in whom the underlying biomechanical or nutritional contributing factors have not been addressed.

Addressing Underlying Risk Factors

Effective long-term management extends beyond the fracture itself. Contributing factors such as low bone density, relative energy deficiency in sport (RED-S), training load errors, and biomechanical abnormalities — including forefoot varus, reduced ankle dorsiflexion, and overpronation — must be identified and corrected. Nutritional assessment, particularly for calcium, vitamin D, and overall energy availability, is an important adjunct to physical treatment. Footwear and orthotic modification may reduce repetitive stress concentration in susceptible individuals.

Navicular stress fractures demand respect. Their insidious onset, diagnostic difficulty, and potential for serious complications make them one of the more exacting injuries encountered in sports medicine. The foundation of successful treatment — whether operative or conservative — is strict non-weight-bearing immobilisation, confirmed radiological healing before load reintroduction, and a patient, structured return-to-sport progression. For the athlete, the prognosis with appropriate management is generally favourable; for those whose treatment is delayed or inadequate, the consequences can be career-defining. Vigilance in diagnosis and discipline in rehabilitation remain the clinician’s most powerful tools.

The Navicular Drop Test: An Assessment Tool for Foot Pronation

The foot is one of the most mechanically complex structures in the human body, comprising 26 bones, 33 joints, and over 100 muscles, tendons, and ligaments working in concert to support posture, absorb shock, and propel movement. Among the many clinical tools used to assess foot mechanics, the navicular drop test stands out for its simplicity, low cost, and diagnostic relevance. First described by Brody in 1982, the navicular drop test has since become a widely used clinical measure of foot pronation, helping practitioners identify biomechanical abnormalities that may contribute to a range of musculoskeletal injuries.

Anatomy and Background

The navicular bone sits on the medial aspect of the midfoot, acting as a keystone of the medial longitudinal arch. It articulates with the talus posteriorly and the three cuneiform bones anteriorly, making it a critical load-transfer point. When the foot pronates — that is, when the arch flattens and the foot rolls inward — the navicular descends toward the ground. Conversely, when the foot supinates or the arch rises, the navicular elevates. This vertical displacement of the navicular serves as a reliable proxy for the degree of pronation occurring across the subtalar and midtarsal joints.

Excessive pronation is a well-documented risk factor for numerous lower limb conditions, including plantar fasciitis, tibialis posterior tendon dysfunction, patellofemoral pain syndrome, medial tibial stress syndrome (shin splints), and iliotibial band syndrome. Because the navicular bone is palpable and its position can be measured with simple tools, the navicular drop test offers clinicians a practical and repeatable means of quantifying arch deformation under load.

Procedure

The navicular drop test is performed in two stages: measurement in a subtalar neutral position and then in a relaxed bilateral standing position.

In the first stage, the patient sits with their foot resting passively on the floor, with the knee flexed to approximately 90 degrees. The clinician palpates the head of the talus on the medial aspect of the foot to find the subtalar neutral position — the point at which the talus is neither pronated nor supinated, identified when the talar head is equally palpable on both its medial and lateral aspects. Once this neutral position is established, the clinician marks the most inferior aspect of the navicular tuberosity with a pen or marking device, and measures its height from the floor using a ruler or index card. This constitutes the “sitting” or non-weight-bearing navicular height.

In the second stage, the patient stands bilaterally with their weight evenly distributed. The foot naturally relaxes into its functional pronated position under the influence of body weight and gravity. The clinician again measures the height of the navicular tuberosity from the floor in this standing position.

The navicular drop value is calculated as the difference between the sitting (neutral) navicular height and the standing (relaxed) navicular height. This number, expressed in millimetres, reflects how far the navicular descends when the foot moves from a non-weight-bearing neutral alignment to a loaded, functional position.

Interpretation

A navicular drop of less than 10 mm is generally considered within normal range, though some authors use a threshold of 5 to 9 mm as the accepted reference range for typical foot mechanics. A drop of 10 mm or greater is widely cited as indicative of excessive pronation, sometimes referred to as a hyperpronated or flatfoot posture. Values of 15 mm or more suggest significantly altered arch mechanics and may warrant further investigation or intervention.

However, it is important to note that normal values can vary based on age, sex, body mass index, and activity level. Athletes, particularly runners, may present with slightly higher navicular drop values without experiencing any pathology. Clinical interpretation should therefore always consider the broader context of the patient’s history, symptoms, and physical findings.

Reliability and Validity

The navicular drop test has been the subject of considerable research examining its psychometric properties. Intra-rater reliability — the consistency of measurements taken by the same clinician on the same patient — is generally reported as good to excellent, with intraclass correlation coefficients (ICCs) typically ranging from 0.78 to 0.95 in various studies. Inter-rater reliability, or consistency between different clinicians, is somewhat more variable, with ICCs ranging from moderate to good. This variability is largely attributed to differences in identifying the subtalar neutral position, which requires clinical skill and experience to determine accurately.

In terms of validity, several studies have found that the navicular drop test correlates meaningfully with more sophisticated three-dimensional gait analysis measurements of rearfoot eversion and arch deformation. It has also demonstrated associations with injury risk in athletic populations. A prospective study in military recruits found that higher navicular drop values were associated with increased rates of overuse injuries during training, lending support to the test’s clinical relevance.

Limitations

Despite its utility, the navicular drop test has several important limitations. First, the process of finding subtalar neutral position introduces a degree of subjectivity and requires training to perform consistently. Second, the test measures static arch deformation rather than dynamic foot function during walking or running, which limits its ability to capture the full complexity of foot mechanics in motion. Third, it assesses only the medial longitudinal arch and does not account for transverse arch behaviour or forefoot mechanics.

Furthermore, the test does not distinguish between the contributions of different anatomical structures to arch collapse — whether the deficit lies in passive ligamentous support, active muscular control (particularly tibialis posterior), or bony morphology. This distinction may be important for guiding treatment.

Clinical Applications

Despite these limitations, the navicular drop test remains a valuable part of the clinical assessment toolkit. It is routinely used in sports medicine, podiatry, physiotherapy, and orthopaedic settings to screen for excessive pronation, guide orthotic prescription, monitor treatment response, and contribute to injury risk stratification. Its simplicity, low cost, and reasonable reliability make it accessible in virtually any clinical environment without the need for expensive motion capture technology.

The navicular drop test represents an elegant solution to a clinical challenge: how to quantify a complex, three-dimensional biomechanical event using simple, low-tech means. While it is not without limitations, its combination of accessibility, reasonable reliability, and clinical meaningfulness has secured its place in the assessment of foot and lower limb mechanics. Used thoughtfully alongside other clinical findings, it remains an important tool in the understanding and management of foot-related pathology.